The SPDR S&P Biotech ETF (XBI) rose 2.42% on October 20, 2026, closing at $147.87 as biotech shares broadly recovered ground in Tuesday's session.
Despite the single-day advance, the fund's recent performance tells a more cautious story. XBI has declined 2.33% over the past seven days and is down 5.58% over the trailing 30-day period, reflecting sustained pressure on the biotech sector.
The Tuesday gain partially offset those losses but was not enough to reverse the downward trend that has defined the fund's performance over the past month. Market capitalization data for the ETF was not available as of the reporting date.
XBI tracks an equal-weighted index of U.S.-listed biotechnology companies, making it a widely followed barometer for sentiment across the broader biotech space.
